Patents Examined by Kahsay Habte
  • Patent number: 11827644
    Abstract: The present invention relates to a pyrazine derivative, an application thereof in inhibiting SHP2, and a compound of formula (I) or pharmaceutically acceptable salts, esters, isomers, solvates, prodrugs or isotope labels thereof. The structure of the compound of formula (I) is as follows. The novel pyrazine derivative provided by the present invention has excellent inhibition of SHP2 activity and can be used to prevent and/or treat non-receptor protein tyrosine phosphatase-mediated or dependent diseases or disorders.
    Type: Grant
    Filed: January 25, 2023
    Date of Patent: November 28, 2023
    Assignee: SUZHOU GENHOUSE PHARMACEUTICAL CO., LTD
    Inventors: Haifeng Sun, Kuifeng Wang, Tao Zhang, Mengnan Ma, Jinchang Lu
  • Patent number: 11820762
    Abstract: The subject invention pertains to compositions and methods for treating neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), multiple sclerosis, epilepsy, stroke, alcohol withdrawal, progressive supranuclear palsy (PSP), Pick's disease (PiD), corticobasal degeneration (CBD), frontotemporal dementia or parkinsonism linked to chromosome 17 (FTDP-17). The methods of the subject invention further relate to methods of fermentation of bacterial cells and methods of tautomerization of the subject compounds.
    Type: Grant
    Filed: September 15, 2021
    Date of Patent: November 21, 2023
    Assignees: The Hong Kong University of Science and Technology, Southern Marine Science and Engineering Guangdong Laboratory (Guangzhou)
    Inventors: Pei-Yuan Qian, Aifang Cheng, Changdong Liu, Wenkang Ye, Guang Zhu
  • Patent number: 11820776
    Abstract: The present disclosure relates to novel processes for the preparation of short acting benzodiazepines as well as to novel intermediates in this process. More particularly the disclosure relates to processes and intermediates for preparation of Methyl 3-[(4S)-8-bromo-1-methyl-6-(pyridin-2-yl)-4H-imidazo[1,2-a][1,4]benzodiazepin-4-yl]propanoate, commonly known as Remimazolam. The present disclosure also relates to solid state forms of Remimazolam salts, processes for the preparation thereof, pharmaceutical formulations/compositions thereof, and methods of use thereof.
    Type: Grant
    Filed: May 24, 2021
    Date of Patent: November 21, 2023
    Assignee: ASSIA CHEMICAL INDUSTRIES LTD.
    Inventors: Dolitzky Ben-Zion, Mendelovici Marioara, Bodkhe Arjun Rajaram, Mane Ganesh Shivaji, Samala Rajamouli Srihari, Joshi Ashutosh Vijay, Parven Kumar Luthra, Amit Singh, Anantha Rajmohan Muthusamy
  • Patent number: 11814371
    Abstract: The present application relates to the field of medicine. Specifically, disclosed are a compound of formula (I), a preparation method therefor, and a pharmaceutical composition comprising the compound.
    Type: Grant
    Filed: March 4, 2021
    Date of Patent: November 14, 2023
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Guanglong Sun, Chunli Shen, Chengde Wu, Shuhui Chen
  • Patent number: 11814399
    Abstract: A synthetic protocol to use a thiourea or urea compound and auric chloride as starting materials to obtain thiazole and benzothiazole derivatives. The synthesis can be conducted at room temperature and the final compound can result from cyclization of the thiourea or urea compound in the presence of an Au salt from the auric chloride.
    Type: Grant
    Filed: April 7, 2023
    Date of Patent: November 14, 2023
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Awal Noor, Ezzat Khan, Umar Ali Khan
  • Patent number: 11807650
    Abstract: Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.
    Type: Grant
    Filed: January 27, 2022
    Date of Patent: November 7, 2023
    Assignee: Novartis AG
    Inventors: David R. Anderson, Robert Volkmann, Frank Menniti, Christopher Fanger, Yuelian Xu
  • Patent number: 11807607
    Abstract: The aminocarbazole compounds are antibacterial agents. The emergence of drug-resistant bacteria calls for constant development of new antibacterial agents with the aim of generating medicaments that are potent against drug sensitive and resistant bacteria and are well tolerated. The present compounds are not only new, but have very valuable antimicrobial properties. These compounds showed a broad spectrum of activity against gram-positive and gram-negative bacteria, as well tuberculosis mycobacteria. They also showed potent activity against drug-resistant bacteria, such as MRSA and VRSA. The molecular target of these compounds was identified as DNA Gyrase B. Based on their pharmacological profiles, the present compounds may find important clinical applications for severe infectious diseases and tuberculosis.
    Type: Grant
    Filed: March 29, 2023
    Date of Patent: November 7, 2023
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Christophe Tratrat, Michelyne Haroun
  • Patent number: 11807648
    Abstract: The present invention provides a process for preparing a compound of the formula (II): wherein R2 is unsubstituted alkyl, characterized by reacting a compound of the formula (I): wherein R1 is hydrogen or a protecting group other than unsubstituted alkyl, with a compound of the formula: R2—OH, wherein R2 is as defined above, in the presence of a sodium salt and/or a magnesium salt.
    Type: Grant
    Filed: January 19, 2022
    Date of Patent: November 7, 2023
    Assignee: SHIONOGI & CO., LTD.
    Inventor: Setsuya Shibahara
  • Patent number: 11807635
    Abstract: Disclosed is a nitrile derivative compound represented by formula (I), a stereoisomer, a deuterated product, a co-crystal, a solvate or a pharmaceutically acceptable salt thereof, wherein each group is as defined in the description. The compound has dipeptidyl peptidase 1 inhibitory activity and can be used to prepare a drug for treating diseases including obstructive airway diseases, bronchiectasis, cystic fibrosis, asthma, emphysema, and chronic obstructive pulmonary diseases.
    Type: Grant
    Filed: October 28, 2022
    Date of Patent: November 7, 2023
    Assignee: Haisco Pharmaceuticals Pte. Ltd.
    Inventors: Yao Li, Zongjun Shi, Guobiao Zhang, Lei Chen, Wenjing Wang, Xiaobo Zhang, Dengyu Zheng, Bo Xu, Xin Liu, Yajun Wang, Fei Ye, Pingming Tang, Jia Ni, Chen Zhang, Pangke Yan
  • Patent number: 11795179
    Abstract: Novel first-in-class imidazothiazole- and imidazooxazole-based potent and selective HER4 kinase inhibitors for therapeutic formulations and methods for treating cancer.
    Type: Grant
    Filed: December 30, 2020
    Date of Patent: October 24, 2023
    Assignee: UNIVERSITY OF SHARJAH
    Inventor: Mohammed El-Gamal
  • Patent number: 11779912
    Abstract: This invention relates generally to olefin metathesis catalyst compounds, to the preparation of such compounds, compositions comprising such compounds, methods of using such compounds, articles of manufacture comprising such compounds, and the use of such compounds in the metathesis of olefins and olefin compounds. The invention has utility in the fields of catalysts, organic synthesis, polymer chemistry, and industrial and fine chemicals industry.
    Type: Grant
    Filed: August 27, 2021
    Date of Patent: October 10, 2023
    Assignees: UMICORE AG & Co. KG, CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Adam M. Johns, Jessica R. Herron, Richard L. Pederson, Bryan A. Fiamengo, Jennifer A. Beerman, Tzu-Pin Lin, Crystal K. Chu, Robert H. Grubbs
  • Patent number: 11780809
    Abstract: The N-(6-substitutedcarbazol-2-yl) acetamide compounds are antibacterial agents. The emergence of drug-resistant bacteria calls for constant development of new antibacterial agents with the aim of generating medicaments that are potent against drug sensitive and resistant bacteria and are well tolerated. The present compounds are not only new, but have very valuable antimicrobial properties. These compounds showed a broad spectrum of activity against gram-positive and gram-negative bacteria, as well tuberculosis mycobacteria. They also showed potent activity against drug-resistant bacteria, such as MRSA and VRSA. The molecular target of these compounds was identified as DNA Gyrase B. Based on their pharmacological profiles, the present compounds may find important clinical applications for severe infectious diseases and tuberculosis.
    Type: Grant
    Filed: March 9, 2023
    Date of Patent: October 10, 2023
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Christophe Tratrat, Michelyne Haroun
  • Patent number: 11773111
    Abstract: Novel dual 5-LO inhibitors of well validated electrophilic Michael acceptors and nitrogen-heterocycles are presented and designed to maintain specific structural features of currently known dual 5-LO inhibitors and to overcome their drawbacks. The Michael acceptor scaffold will act as a carrier and will provide a stable anchorage via covalent binding to cysteine/histidine residues within the catalytic cleft and/or the surface interface of the 5-LO; whereas, the nitrogen-heterocycles will ensure the access to the Fe(II) catalytic center. These combinations offer potential for more than one mode of iron chelation and 5-LO inhibition.
    Type: Grant
    Filed: November 29, 2022
    Date of Patent: October 3, 2023
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Saadeldin Elsayed Ibrahim Shabaan, Hany Mohamed Abd El-Lateef Ahmed
  • Patent number: 11773052
    Abstract: Provided are a donor-acceptor type compound having a novel structure and its use.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: October 3, 2023
    Assignee: JAPAN SCIENCE AND TECHNOLOGY AGENCY
    Inventors: Hideo Nagashima, Atsushi Tahara, Ikumi Kitahara, Yoichiro Kuninobu
  • Patent number: 11773086
    Abstract: The present invention is directed to compounds, compositions, and methods for inhibiting drug-efflux pumps. The compounds, compositions, and methods can be used for enhancing the activity of therapeutic agents that are efflux pump substrates and for the treatment of drug-resistant diseases or disorders, such as microbial infections and cancers.
    Type: Grant
    Filed: August 31, 2021
    Date of Patent: October 3, 2023
    Assignees: TRUSTEES OF BOSTON UNIVERSITY, THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO
    Inventors: Lauren E. Brown, Kaddy Camara, Leah E. Cowen, John A. Porco, Jr., Kali Rae Iyer
  • Patent number: 11759462
    Abstract: The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.
    Type: Grant
    Filed: March 15, 2021
    Date of Patent: September 19, 2023
    Inventors: Stéphane De Lombaert, Daniel R. Goldberg, Kenneth Brameld, Eric Brian Sjogren, Andrew Scribner
  • Patent number: 11746095
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Grant
    Filed: May 6, 2022
    Date of Patent: September 5, 2023
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Stephen W. Kaldor, Toufike Kanouni, Eric Murphy, Jason Cox, Robert Kania
  • Patent number: 11746100
    Abstract: The subject matter described herein is directed to ferroportin inhibitor compounds of Formula I or I? and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.
    Type: Grant
    Filed: April 28, 2021
    Date of Patent: September 5, 2023
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Qing Xu, Carsten Alt, Zhe Li, Shahul Nilar, Peter Michael Rademacher, Calvin Wesley Yee
  • Patent number: 11731964
    Abstract: The present invention generally relates to compounds as a new antibiotic to treat various infections, including infections caused by methicillin-resistant Staphylococcus aureus, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecalis and Clostridioides difficile. Pharmaceutical compositions and methods for treating those diseases are within the scope of this invention.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: August 22, 2023
    Assignee: Purdue Research Foundation
    Inventors: Herman O. Sintim, Mohamed Seleem, Clement Opoku-Temeng, Haroon Taj Mohammad, George Naclerio
  • Patent number: 11731939
    Abstract: The indole-based chalcone compounds are antibacterial agents. The emergence of drug-resistant bacteria calls for constant development of new antibacterial agents with the aim of generating medicaments that are potent against drug sensitive and resistant bacteria and are well tolerated. The present compounds are not only new, but have very valuable antimicrobial properties. These compounds showed a broad spectrum of activity against gram-positive and gram-negative bacteria, as well tuberculosis mycobacteria. They also showed potent activity against drug-resistant bacteria, such as MRSA and VRSA. The molecular target of these compounds was identified as DNA Gyrase B. Based on their pharmacological profiles, the present compounds may find important clinical applications for severe infectious diseases and tuberculosis.
    Type: Grant
    Filed: March 7, 2023
    Date of Patent: August 22, 2023
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Christophe Tratrat, Michelyne Haroun